引用本文
  • 叶博文,陈毅来,张晏玮,等.循环肿瘤DNA液态活检检测微小残留病在实体肿瘤诊疗中的研究进展[J].同济大学学报(医学版),2024,45(2):290-296.    [点击复制]
  • YE Bowen,CHEN Yilai,ZHANG Yanwei,et al.Research progress of circulating tumor DNA liquid biopsy for detection of minimal residual disease in the diagnosis and management of solid tumors[J].同济大学学报(医学版),2024,45(2):290-296.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 44次   下载 68 本文二维码信息
码上扫一扫!
循环肿瘤DNA液态活检检测微小残留病在实体肿瘤诊疗中的研究进展
叶博文,陈毅来,张晏玮,叶林
0
(同济大学附属东方医院泌尿外科,上海200120;克拉玛依市人民医院泌尿外科,新疆834099)
摘要:
基于液态活检的微小残留病(minimal residual disease, MRD)检测在各肿瘤疾病的应用中具有巨大的潜力,随着基因测序技术和生物信息学的发展,二代测序(next-generation sequencing, NGS)作为一种新兴的MRD检测技术,可以对循环肿瘤DNA(circulation tumor DNA, ctDNA)进行定量和定性分析,目前在多种实体瘤中的应用均具有高灵敏度和高特异度。多项研究已证实基于ctDNA的MRD检测结果与患者复发预测、预后判断、疗效评估及个体化分层治疗均有临床相关性,且相较于传统临床手段优势明显。但目前ctDNA MRD的检测技术应用于常规临床实践仍需要大量临床数据的支持,检测方法的统一标准仍未建立。
关键词:  循环肿瘤DNA  微小残留病  实体肿瘤  液体活检  检测方法  临床应用
DOI:10.12289/j.issn.2097-4345.23142
投稿时间:2023-04-29
基金项目:国家自然科学基金面上项目(81972409)
Research progress of circulating tumor DNA liquid biopsy for detection of minimal residual disease in the diagnosis and management of solid tumors
YE Bowen,CHEN Yilai,ZHANG Yanwei,YE Lin
(Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China;Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China; Department of Urology, Karamay People’s Hospital, Karamay 834099, Xinjiang Uygur Autonomous Region, China)
Abstract:
Liquid biopsy-based detection of minimal residual disease(MRD) has been widely used in clinical oncology. The next general sequencing(NGS), as an emerging technique of MRD detection provides quantitative and qualitative analysis of circulating tumor DNA(ctDNA) for solid tumors with high sensitivity and high specificity. Recent studies have demonstrated that the ctDNA-based MRD detection has significant advantages over traditional methods in recurrence prediction, prognosis determination, efficacy assessment and individualized stratified treatment of various malignant tumors. However, for its routine clinical application large amount of clinical evidence are needed and the standardization of detection methods is required.
Key words:  circulating tumor DNA  minimal residual disease  solid tumor  liquid biopsy  detection method  clinical application

您是第5268140位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计